RELINFO - Brazilian Network for Lymphoma Registry in Rio de Janeiro: Preliminary Results

Abstracts end-point. Results: Complete response (CR) was achieved in 5 patients (13.5%), CR unconfirmed in three (8%), and partial response in 12 (32.4%) for an overall response rate of 54%. Median progression-free survival was 2.1 months (95% CI, 1.1 to 3.0 months). The most frequent CTC  3 adverse events were: hyperglycemia (29.7% patients), thrombocytopenia (21.6%), infection (19%) and anemia (10.8%). The mean maximum blood concentration was 292 ng/mL for temsirolimus and 37.2 ng/mL for sirolimus in the 25-mg cohort and 484 ng/mL and 91.1 ng/ mL, respectively, in the 75-mg cohort. Temsirolimus CSF concentration was 2 ng/mL in one patient (75 mg cohort) and not detectable in all others. Conclusions: Single-agent temsirolimus at a weekly dose of 75 mg was active in r/rPCNSL; however, responses were usually short lived. Cellular feedbacks resulting in e.g. upregulation of AKT could be the reason of resistance to temsirolimus. Dual pan-PI3K/mTOR inhibitors of both mTORC1/TORC2 and the upstream PI3K isoforms lead to a G1/ S arrest and robust autophagy without unintended upregulation of AKT. A trans-atlantic study with an oral dual PI3K/mTOR inhibitor PQR309 in r/rPCNSL (NCT02669511) is currently ongoing with 5 patients recruited thus far. At the meeting, first experience will be presented.

NHL-128 RELINFO - Brazilian Network for Lymphoma Registry in Rio de Janeiro: Preliminary Results Leonardo Gomes ,7,10 Adriana Scheliga,1 Marcio Hori,2 Monica Prexedes,3 Fernando Monteiro,4 Marilza Magalhães,5 Rita Spariz,6 Kellen Blanco,8 Luciana Conti,9 Glaucia Guasti,10 Solange Elehep11 1

Instituto Nacional Do Cancer, Rio de Janeiro, Brazil; 2Instituto COI de Educação e Pesquisa, Rio de Janeiro, Brazil; 3Hospital Universitário

Figure 1 Most Common NHL Subtypes in RELINFO Registry

HL. The majority was female (52.2%). The mean age was 47 years. Most common NHL subtypes are shown in Figure 1. Nodular sclerosis represented the most common HL subtype (64.2%). The average time between the symptons onset and diagnosis was 5.3 months. Median time between diagnosis and start of treatment was 24 days. Four pts died before receiving any treatment due to advanced disease. Among HL 96% had primary nodal disease most frequently in the cervical region (33.8%). High IPS3 observed in 32%. Among NHL pts, 23.6% had extranodal disease. High/High intermidiate IPI were identified in 34 pts with NHL. Conclusion: RELINFO is to become a reliable lymphoma registry and a menagement model to be replicated nationwide, providing subsidies for the development of clinical studies, given the large number of new strategies and therapeutic options. Financial Support: FAPERJ Proc E-26/111.429/2012

Antônio Pedro (HUAP/UFF); 4Hospital Federal da Lagoa (HFL), Rio de Janeiro, Brazil; 5Hospital Universitário Gaffrée e Guinle (HUGG/UNIRIO), Rio de Janeiro, Brazil; 6Hospital Federal Cardoso Fontes 7

(HFCF), Rio de Janeiro, Brazil; IDOR - Instituto D’Or Pesquisa e Ensino, Rio de Janeiro, Brazil; 8Hospital de Força Aérea do Galeão (HFAG), Rio de Janeiro, Brazil; 9Oncoclínica Centro de Tratamento Oncológico Ltda., Rio de Janeiro, Brazil; 10Hospital Central do Exercito (HCE), Rio de Janeiro, Brazil; 11Hospital Central da Policia Militar do Estado do Rio de Janeiro (HCPM), Rio de Janeiro, Brazil

Introduction: There are few data in the incidence, monitoring and prognosis of lymphomas patients in Brazil. Objective: Describe the lymphoma patients (pts) clinical profile enrolled in 11 different public and private institutions paticipating at RELINFO in 2014. Methodology: RELINFO (ClinicalTrials.gov:NTC02265497) is a multicenter, observacional, prospective study intended to collect clinical, histopathological, molecular and treatment data from pts diagnosed with Hodgkin’s Lymphoma (HL) and non-Hodgkin’s Lymphoma (NHL). The web-based platform was developed using OpenClinica case report forms. INCA is the Coodinator Center. Results: There were 180 eligible pts, 127 (70%) with NHL and 53 (30%) with

S108

-

Clinical Lymphoma, Myeloma & Leukemia September 2016

NHL-131 Novel BRD4-Degrading Proteolysis Targeting Chimera (PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma (MCL) Cells Kapil Bhalla , Baohua Sun, Warren Fiskus, Liang Zhang, Dyana Saenz, Christopher Mill, Michael Wang Departments of Leukemia and Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

MCL cells exhibit chronic-active BCR signaling and downstream pro-growth and pro-survival NFkB activity. Ibrutinib, a covalent inhibitor of Bruton’s tyrosine kinase (BTK) yields high overall response rate in relapsed/refractory MCL, but approximately 40% of patients demonstrate primary refractory/resistant disease. Mutations in CARD11/IKBKB/